A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

February 4, 2025

Study Completion Date

February 4, 2025

Conditions

Adhesive Capsulitis

Interventions

DRUG

Corticosteroid

Triamcinolone 20 mg (1cc)

OTHER

ActiveMatrix

1cc ActiveMatrix (Skye Biologics, Inc.)

DRUG

Lidocaine

Lidocaine 10 mg/mL (5cc)

Trial Locations (1)

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors

collaborator

Skye Biologics, Inc.

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER